ANDA 78966, held by Strides Pharma International. Omeprazole; Sodium Bicarbonate.
As of Nov 21, 2026, ANDA 78966 (Omeprazole and Sodium Bicarbonate), held by Strides Pharma International, was first approved by FDA on May 25, 2010, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 25, 2010 | Original application | Approved |
| Omeprazole and Sodium Bicarbonate20MG;1.1GM ยท capsule;oral | Omeprazole; Sodium Bicarbonate | Discontinued |
| Omeprazole and Sodium Bicarbonate40MG;1.1GM ยท capsule;oral | Omeprazole; Sodium Bicarbonate | Discontinued |
| Dec 19, 2023 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Dec 19, 2023 | Supplement 12Labeling ยท Standard review | Approved | None posted |
| Jul 20, 2020 | Supplement 9Labeling ยท Standard review | Approved | None posted |
| Apr 9, 2015 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Aug 27, 2012 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Mar 13, 2012 | Supplement 3Labeling | Approved | None posted |
| Mar 13, 2012 | Supplement 4Labeling | Approved | None posted |
| Mar 13, 2012 | Supplement 5Labeling | Approved | None posted |
| May 25, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters